NCT00085787View on ClinicalTrials.gov

A Study of ARRY-142886 in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Advanced Cancer
Interventions
DRUG

ARRY-142886, MEK inhibitor; oral

Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule

Trial Locations (3)

19111

Fox Chase Cancer Center, Philadelphia

55905

Mayo Clinic Rochester, Rochester

80010

University of Colorado Cancer Center, Anschutz Cancer Center, Aurora

All Listed Sponsors
lead

Array Biopharma, now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00085787 - A Study of ARRY-142886 in Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter